1. Munson P.J., Rodbard D. (1988). An exact correction to the "Cheng-Prusoff" correction. J Recept Res 8:533-46.

2. Cheng Y., Prusoff W.H. (1973). Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-108.

3. Brandt R.B., Laux J.E., Yates S.W. (1987). Calculation of inhibitor Ki and inhibitor type from the concentration of inhibitor for 50% inhibition for Michaelis-Menten enzymes. Biochem Med Metab Biol 37:344-9.

4. Lazareno S., Birdsall N.J. (1993). Estimation of competitive antagonist affinity from functional inhibition curves using the Gaddum, Schild and Cheng-Prusoff equations. Br J Pharmacol 109:1110-9.

5. Henderson, P.J. (1972) A linear equation that describes the steady-state kinetics of enzymes and subcellular particles interacting with tightly bound inhibitors. Biochem. J., 127:321-333.

6. Copeland, R.A., Lombardo, D., Giannaras, J., Decicco, C.P. (1995) Estimating KI values for tight binding inhibitors from dose-response plots Bioorg. Med. Chem. Lett., 5:1947-1952.

7. Cheng H.C. (2001). The power issue: determination of KB or Ki from IC50. A closer look at the Cheng-Prusoff equation, the Schild plot and related power equations. J Pharmacol Toxicol Methods 46:61-71.

8. Huang X. (2003). Fluorescence polarization competition assay: the range of resolvable inhibitor potency is limited by the affinity of the fluorescent ligand. J Biomol Screen 8:34-8.

9. Nikolovska-Coleska Z., Wang R., Fang X., Pan H., Tomita Y., Li P., Roller P.P., Krajewski K., Saito N.G., Stuckey J.A., Wang S. (2004). Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarization. Anal Biochem 332:261-73.

10. Lebeda, F.J., Adler, M., Erickson, K., Chushak, Y. (2008) Onset dynamics of type A botulinum neurotoxin-induced paralysis. J. Pharmacokinet. Pharmacodyn., 35:251-67.

11. Craig, D.A. (1993) The Cheng-Prusoff relationship: something lost in the translation. Trends Pharmacol. Sci., 14:89-91.

12. Mudunuri U., Stephens R., Bruining D., Liu D. and Lebeda F.J. (2006). botXminer: mining biomedical literature with a new web-based application. Nucleic Acids Research 34:W748-W752.

13. Barthelmes, J., Ebeling, C., Chang, A., Schomburg, I., Schomburg, D. (2007) BRENDA, AMENDA and FRENDA: the enzyme information system in 2007. Nucleic Acids Res., 35:D511-D514.

14. Greene, J.M., Collins, F., Lefkowitz, E.J., Roos, D., Scheuermann, R.H., Sobral, B., Stevens, R., White, O., Di Francesco, V. (2007) National Institute of Allergy and Infectious Diseases bioinformatics resource centers: new assets for pathogen informatics. Infect. Immun., 75:3212-3219.

15. Berman, H.M., Westbrook, J.D., Gabanyi, M.J., Tao, W., Shah, R., Kouranov, A., Schwede, T., Arnold, K., Kiefer, F., Bordoli, L., Kopp, J., Podvinec, M., Adams, P.D., Carter, L.G., Minor, W., Nair, R., La Baer, J. (2009) The protein structure initiative structural genomics knowledgebase. Nucleic Acids Res., 37:D365-D368.

16. Fowler, C.J., Strolin Benedetti, M. (1983) Cimoxatone is a reversible tight-binding inhibitor of the A form of rat brain monoamine oxidase. J. Neurochem., 40:510-513.

17. Burnett, J.C., Opsenica, D., Sriraghavan, K., Panchal, R.G., Ruthel, G., Hermone, A.R., Nguyen, T.L., Kenny, T.A., Lane, D.J., McGrath, C.F., Schmidt, J.J., Vennerstrom, J.L., Gussio, R., Solaja, B.A., Bavari, S. (2007) A refined pharmacophore identifies potent 4-amino-7-chloroquinoline-based inhibitors of the botulinum neurotoxin serotype A metalloprotease. J. Med. Chem., 50:2127-2136.

18. Marechal, J.D., Yu, J., Brown, S., Kapelioukh, I., Rankin, E.M., Wolf, C.R., Roberts, G.C., Paine, M.J., Sutcliffe, M.J. (2006) In silico and in vitro screening for inhibition of cytochrome P450 CYP3A4 by comedications commonly used by patients with cancer. Drug Metab. Dispos., 34:534-8.

19. Cheng H.C. (2004). The influence of cooperativity on the determination of dissociation constants: examination of the Cheng-Prusoff equation, the Scatchard analysis, the Schild analysis and related power equations. Pharmacol Res. 2004 Jul;50(1):21-40.